Difficulty: Medium
Average Score: 83%
Practice
A 72-year-old woman with Parkinson's disease is taking a medication that increases release of dopamine, blockade of cholinergic receptors, and inhibiting the N-methyl-D-aspartate receptor. This describes which of the following agents?
Correct answer
A
Rationale
The correct answer is A) Amantadine. Amantadine is a medication used in Parkinson's disease that works by increasing the release of dopamine, blocking cholinergic receptors, and inhibiting the N-methyl-D-aspartate receptor.
- Amantadine works by increasing dopamine release, which helps to alleviate some of the symptoms of Parkinson's disease related to dopamine deficiency.
- Blocking cholinergic receptors helps to rebalance the neurotransmitter systems in the brain, as an imbalance between dopamine and acetylcholine is a hallmark of Parkinson's disease.
- Inhibiting the N-methyl-D-aspartate receptor can help reduce excitotoxicity and neurodegeneration seen in Parkinson's disease.
Why the other options are incorrect:
- B) Bromocriptine is a dopamine agonist that works by directly stimulating dopamine receptors, not by increasing dopamine release or acting on cholinergic receptors.
- C) Pramipexole is also a dopamine agonist, not a medication that acts on cholinergic receptors or NMDA receptors.
- D) Rotigotine is a dopamine agonist delivered through a transdermal patch and does not have the same mechanism of action as described in the question.
Educational context:
Understanding the mechanisms of action of CNS drugs is crucial in pharmacology to ensure appropriate medication selection based on the underlying pathophysiology of the condition being treated. In the case of Parkinson's disease, a combination of medications with different mechanisms of action may be used to target various aspects of the disease process and provide optimal symptom management for patients.
- Amantadine works by increasing dopamine release, which helps to alleviate some of the symptoms of Parkinson's disease related to dopamine deficiency.
- Blocking cholinergic receptors helps to rebalance the neurotransmitter systems in the brain, as an imbalance between dopamine and acetylcholine is a hallmark of Parkinson's disease.
- Inhibiting the N-methyl-D-aspartate receptor can help reduce excitotoxicity and neurodegeneration seen in Parkinson's disease.
Why the other options are incorrect:
- B) Bromocriptine is a dopamine agonist that works by directly stimulating dopamine receptors, not by increasing dopamine release or acting on cholinergic receptors.
- C) Pramipexole is also a dopamine agonist, not a medication that acts on cholinergic receptors or NMDA receptors.
- D) Rotigotine is a dopamine agonist delivered through a transdermal patch and does not have the same mechanism of action as described in the question.
Educational context:
Understanding the mechanisms of action of CNS drugs is crucial in pharmacology to ensure appropriate medication selection based on the underlying pathophysiology of the condition being treated. In the case of Parkinson's disease, a combination of medications with different mechanisms of action may be used to target various aspects of the disease process and provide optimal symptom management for patients.